Here is the link to my Google Scholar account.
Representative Patent:
Compositions and Methods for Treating Infections of the Gastrointestinal Tract. J Faith, V Aggarwala, L Bethlehem, JJ Eggers 2023
Representative Publications:
As a Postdoctoral Fellow: "Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes", Aggarwala et. al., Nature Microbiology 2021
As a PhD Scholar: "An expanded sequence context model broadly explains variability in polymorphism levels across the human genome", Aggarwala and Voight, Nature Genetics 2016
The overarching mission of our laboratory is to model microbiome dynamics (gut, skin, vaginal tract) and in-turn identify reproducible live bacterial products, ranging from synbiotics to super-donor stool material, for robust and stable engineering of the human microbiome in both health and disease.
Human body is colonised and is in a symbiotic relationship with trillions of microorganisms (predominantly bacteria) which have a critical role in maintaining health and have been implicated across several diseases. The scientific community is actively perturbing the human microbial communities (probiotics, diet, synbiotics, stool transplant, xenobiotics) for desirable therapeutic outcomes with various degrees of success but several challenges remain:
We have not characterised the vast diversity of our commensal microbes,
Answered fundamental questions pertaining to their mechanism and modes of action,
Barely understand the stability and structure of the complex microbial ecology and how it transforms under a homeostatic state and in presence of external perturbations (FMT, dietary changes, probiotics).
How to reproducibly engineer the microbiota?
Microbiome Therapeutics laboratory is addressing these open questions by integrating ideas from computational systems biology, ecology, genomics, & microbial culturing with fruitful collaborations from clinicians and public health researchers.
We collaborate extensively with clinicians and identify longitudinal microbiota samples (both in health and disease, with matched controls) to develop models and test our hypotheses. In our golden age of publicly available high-quality genomic datasets, we benefit tremendously from repurposing independent studies for our investigations. We also have access to high throughput sequencing and a biobanking facility for our projects. AWS and NSM Param are used for our high performance computing requirements. We will soon have a well-stocked laboratory for benchside research.
PROJECTS:
Our central theme is to engineer the microbiota but this is conditional on modelling and mechanistic understanding of underlying microbial dynamics. Towards this, we are actively pursuing the following projects:
Pangenomic representation of human commensal microbes to model microbiome dynamics in complex social settings (multiple donors, recipients or community with extensive sharing of microbes).
Antibiotic resistance reservoirs: Modelling, stability and engineering techniques to reset it.
Microbiome for Age: Modelling, variation across lifespan, and engineering techniques for microbiome maturity.
Microbiome (im)maturity in children with undernutrition, and symbiotic interventions to reverse cognitive stunting.
Bacterial strain dynamics post Faecal Microbiota Transplants (FMT) for Ulcerative Colitis (UC).
Microbial Predictors for both clinical endpoint and longevity of response post-FMT for UC.
Identification of super stool donors and superior interventional methodologies by integrating 1000s of FMT.
Computational approaches to achieve actionable strain level resolution for commensal microbes.
Core commensal microbiota in early childhood and its impact on the seeding of transient microbes.
FMT registries, donor engraftment (urban vs rural), stool biobanks & hub for Indian microbiota therapeutics.
FUNDING RESOURCES:
Current
Generous startup support from Jio Institute.
DBT Ramalingaswami re-entry fellowship
Previous
PI for Research fellowship award (175,500 USD, 2020-22) from Crohn’s and Colitis Foundation to study microbial strain dynamics in an FMT clinical trial for active Ulcerative Colitis
Co-PI on Pilot grant (50,000 USD, 2019-20) from Genetics and Genomics institute of Icahn School of Medicine at Mount Sinai, to study and design live biotherapeutic product for C. difficile infection
Laboratory philosophy and culture:
We have an open non-hierarchical lab culture and encourage critical discussions and respect independent thoughts.
The PI firmly believes that the success of trainees will be the true barometer of his own success and is committed to ensuring a productive environment that will benefit every stakeholder.
We welcome creative ideas but insist on every project to make a positive impact on therapeutics, and thus contribute to the Atmanirbhar Bharat and Make in India mission to realise our collective civilizational potential in this Amrit kaal.
Postdocs:
Dr Narendra Chaudhry: Narendra is working on pangenomic modelling of commensal microbes to elucidate microbiome dynamics (across complex community settings, FMT interventions) and in turn identify candidates for live bacterial therapeutics.
Dr Agnik Haldar: Agnik is building accurate microbiota for age models, understanding the core commensal features across lifespan, and if microbiome engineering can help with maturity (for age).
RA:
Anish Ganju: Anish is modelling the Antimicrobial resistance (AMR) reservoirs and their stability over time, and if different microbiome perturbations (FMT, synbiotics) can systematically alter the AMR reservoirs in high-risk cohorts.